Biotargeted nanomedicines for cancer: Six tenets before you begin

Nanomedicine

Volumn 8, Issue 2, 2013, Pages 299-308

  Goldberg, Michael S ^a   Hook, Sara S ^b   Wang, Andrew Z ^c   Bulte, Jeff W M ^d   Patri, Anil K ^e   Uckun, Fatih M ^f   Cryns, Vincent L ^g   Hanes, Justin ^j   Akin, Demir ^h   Hall, Jennifer B ^e   Gharkholo, Nastaran ⁱ   Mumper, Russell J ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ University of North Carolina   (United States)

^j NONE

more..

Author keywords

cost effectiveness analysis; good manufacturing practice; ligand; nanoparticle; receptor targeted

Indexed keywords

NANOPARTICLE;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; GOOD MANUFACTURING PRACTICE; HUMAN; NANOMEDICINE; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; ZETA POTENTIAL;

EID: 84873598467     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.3     Document Type: Review

References (59)

1. Nolan BW, Schermerhorn ML, Powell RJ et al. Restenosis in gold-coated renal artery stents. J. Vasc. Surg. 42(1), 40-46 (2005).
2. Park J-H, Von Maltzahn G, Xu MJ et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc. Natl Acad. Sci. USA 107(3), 981-986 (2010).
3. Park J, Gao W, Whiston R, Strom TB, Metcalfe S, Fahmy TM. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle mediated cytokine delivery. Mol. Pharm. 8(1), 143-152 (2011).
4. Agemy L, Friedmann-Morvinski D, Kotamraju VR et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl Acad. Sci. USA 108(42), 17450-17455 (2011).
5. Poon Z, Lee JA, Huang S, Prevost RJ, Hammond PT. Highly stable, ligand-clustered "patchy" micelle nanocarriers for systemic tumor targeting. Nanomedicine (Lond.) 7(2), 201-209 (2011).
6. Yang L, Mao H, Cao Z et al. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology 136(5), 1514.e2-1525.e2 (2009).
7. Yang L, Mao H, Wang YA et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 5(2), 235-243 (2009).
8. McCarthy JR, Korngold E, Weissleder R, Jaffer FA. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 6(18), 2041-2049 (2010).
9. Santra S, Kaittanis C, Santiesteban OJ, Perez JM. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy. J. Am. Chem. Soc. 133(41), 16680-16688 (2011).
10. Wang X, Li J, Wang Y et al. A folate receptor targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 5(8), 6184-6194 (2011).
11. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33(2), 583-591 (2012).
12. Yokoyama T, Tam J, Kuroda S et al. EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells. PLoS One 6(11), e25507 (2011).
13. Alexis F, Basto P, Levy-Nissenbaum E et al. HER 2-targeted nanoparticle-affibody bioconjugates for cancer therapy. Chem. Med. Chem. 3(12), 1839-1843 (2008).
14. Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control. Release 153(1), 16-22 (2011).
15. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
16. Van Oosten M, Crane LM, Bart J, Van Leeuwen FW, Van Dam GM. Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using Target Selection Criteria (TASC): A novel target identification tool. Transl Oncol. 4(2), 71-82 (2011).
17. Yoon DJ, Liu CT, Quinlan DS, Nafisi PM, Kamei DT. Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer. Ann. Biomed. Eng. 39(4), 1235-1251 (2011).
18. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104(39), 15549-15554 (2007).
19. Kirpotin DB, Drummond DC, Shao Y et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732-6740 (2006).
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
21. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev. Res. (Phila.) 3(11), 1361-1364 (2010).
22. Scheel C, Eaton EN, Li SH-J et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145(6), 926-940 (2011).
23. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010).
24. Sengupta S, Eavarone D, Capila I et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436(7050), 568-572 (2005).
25. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci. 102(7), 1247-1252 (2011).
26. Wong C, Stylianopoulos T, Cui J et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. USA 108(6), 2426-2431 (2011).
27. Harris TJ, Von Maltzahn G, Lord ME et al. Protease-triggered unveiling of bioactive nanoparticles. Small 4(9), 1307-1312 (2008).
28. Poon Z, Chang D, Zhao X, Hammond PT. Layer-by-layer nanoparticles with a pH sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano 5(6), 4284-4292 (2011).
29. Wang J, Byrne JD, Napier ME, Desimone JM. More effective nanomedicines through particle design. Small 7(14), 1919-1931 (2011).
30. Kennedy DC, Hoop KA, Tay L-L, Pezacki JP. Development of nanoparticle probes for multiplex SERS imaging of cell surface proteins. Nanoscale 2(8), 1413-1416 (2010).
31. Ko MH, Kim S, Kang WJ et al. In vitro derby imaging of cancer biomarkers using quantum dots. Small 5(10), 1207-1212 (2009).
32. Gindy ME, Prud'homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin. Drug Deliv. 6(8), 865-878 (2009).
33. Thaxton CS, Elghanian R, Thomas AD et al. Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc. Natl Acad. Sci. USA 106(44), 18437-18442 (2009).
34. Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochim. Biophys. Acta 1810(3), 317-329 (2011).
35. Hossann M, Wang T, Wiggenhorn M et al. Size of thermosensitive liposomes influences content release. J. Control. Release 147(3), 436-443 (2010).
36. Rhee M, Valencia PM, Rodriguez MI, Langer R, Farokhzad OC, Karnik R. Synthesis of size-tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer microchannels. Adv. Mater. 23(12), H79-H83 (2011).
37. Rothstein SN, Federspiel WJ, Little SR. A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices. Biomaterials 30(8), 1657-1664 (2009).
38. Hrkach J, Von Hoff D, Ali MM et al. Preclinical development and clinical translation of a PSMA targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl Med. 4(128), 128-139 (2012).
39. Ge J, Neofytou E, Cahill TJ, Beygui RE, Zare RN. Drug release from electric-field-responsive nanoparticles. ACS Nano 6(1), 227-233 (2012).
40. Melancon MP, Zhou M, Li C. Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. Acc. Chem. Res. 44(10), 947-956 (2011).
41. Tyner K, Sadrieh N. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. Methods Mol. Biol. 697, 17-31 (2011).
42. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008).
43. Gaitanis A, Staal S. Liposomal doxorubicin and nAb paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol. Biol. 624, 385-392 (2010).
44. Burgess P, Hutt PB, Farokhzad OC, Langer R, Minick S, Zale S. On firm ground: IP protection of therapeutic nanoparticles. Nat. Biotechnol. 28(12), 1267-1270 (2010).
45. Sharp PA, Langer R. Promoting convergence in biomedical science. Science 333(6042), 527 (2011).
46. Dobrovolskaia MA, Patri AK, Simak J et al. Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol. Pharm. 9(3), 382-393 (2012).
47. Stern ST, Hall JB, Yu LL et al. Translational considerations for cancer nanomedicine. J. Control. Release 146(2), 164-174 (2010).
48. Characterization of Nanoparticles Intended for Drug Delivery. McNeil SE (Ed.). Humana Press Inc., NY, USA (2011).
49. Roebben G, Ramirez-Garcia S, Hackley VA et al. Interlaboratory comparison of size and surface charge measurements on nanoparticles prior to biological impact assessment. J. Nanopart. Res. 13(7), 2675-2687 (2011).
50. Boeckler C, Frisch B, Muller S, Schuber F. Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. J. Immunol. Methods 191(1), 1-10 (1996).
51. Leonov AP, Zheng J, Clogston JD, Stern ST, Patri AK, Wei A. Detoxification of gold nanorods by treatment with polystyrenesulfonate. ACS Nano 2(12), 2481-2488 (2008).
52. Zara J, Pomato N, McCabe RP, Bredehorst R, Vogel CW. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation. Bioconjug. Chem. 6(4), 367-372 (1995).
53. Lo ST, Stern S, Clogston JD et al. Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct. Mol. Pharm. 7(4), 993-1006 (2010).
54. Zolnik BS, Stern ST, Kaiser JM et al. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab. Dispos. 36(8), 1709-1715 (2008).
55. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61(6), 428-437 (2009).
56. Simanek E, Patri AK. Biodistribution of nanomedicines. Mol. Pharm. 5(4), 473 (2008).
57. Dobrovolskaia MA, Clogston JD, Neun BW, Hall JB, Patri AK, McNeil SE Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett. 8(8), 2180-2187 (2008).
58. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 4(7), 411-414 (2009).
59. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology 151(2), 458-465 (2010).